Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1032-1045

  Kuper Hommel, Marion J J ^a   Van Krieken, J Han J M ^b  

^a WAIKATO DISTRICT HEALTH BOARD   (New Zealand)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical features; Histology; MALT; Marginal zone lymphoma; Molecular pathogenesis

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CHEMOKINE RECEPTOR; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANEMIA; BCL10 GENE; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL SURFACE; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; GENE; HUMAN; LEUKOPENIA; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MALT1 GENE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; UPREGULATION; VOMITING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CASPASES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PATHOLOGY, MOLECULAR; PHENOTYPE; PROGNOSIS;

EID: 84861352769     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.631157     Document Type: Review

References (206)

1. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classifi cation of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-5032.
2. Luminari S, Cesaretti M, Marcheselli L, et al. Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas. Ann Oncol 2010;21:855-859.
3. Luminari S, Cesaretti M, Rashid I, et al. Incidence, clinical characteristics and survival of malignant lymphomas: a populationbased study from a cancer registry in northern Italy. Hematol Oncol 2007;25:189-197
4. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program :307-313.
5. A clinical evaluation of the International Lymphoma Study Group classifi cation of non-Hodgkin ' s lymphoma. The Non-Hodgkin' s Lymphoma Classifi cation Project. Blood 1997;89:3909-3918.
6. Mazloom A, Medeiros LJ, McLaughlin PW, et al. Marginal zone lymphomas: factors that affect the final outcome. Cancer 2010;116:4291-4298.
7. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410-1416. (Pubitemid 13017202)
8. Spencer J, Finn T, Isaacson PG. Human Peyer' s patches: an immunohistochemical study. Gut 1986;27:405-410. (Pubitemid 16102894)
9. Morse HC III, Kearney JF, Isaacson PG, et al. Cells of the marginal zone-origins, function and neoplasia. Leuk Res 2001;25:169-178. (Pubitemid 32141121)
10. Spencer J, Finn T, Isaacson PG. Gut associated lymphoid tissue: a morphological and immunocytochemical study of the human appendix. Gut 1985;26:672-679. (Pubitemid 15044992)
11. Morente M, Piris MA, Orradre JL, et al. Human tonsil intraepithelial B cells: a marginal zone-related subpopulation. J Clin Pathol 1992;45:668-672.
12. Maes B, De Wolf-Peeters C. Marginal zone cell lymphoma-an update on recent advances. Histopathology 2002;40:117-126. (Pubitemid 34122113)
13. van den Oord JJ, De Wolf-Peeters C, De VR, et al. Immature sinus histiocytosis. Light- and electron-microscopic features, immunologic phenotype, and relationship with marginal zone lymphocytes. Am J Pathol 1985;118:266-277. (Pubitemid 15127683)
14. Isaacson PG. Extranodal lymphomas: the MALT concept. Verh Dtsch Ges Pathol 1992;76:14-23.
15. Isaacson PG. Lymphomas of mucosa-associated lymphoid tissue (MALT). Histopathology 1990;16:617-619. (Pubitemid 20183017)
16. Burke JS. Are there site-specific differences among the MALT lymphomas-morphologic, clinical? Am J Clin Pathol 1999;111: S133-S143. (Pubitemid 29024958)
17. Harris NL. Lymphoid proliferations of the salivary glands. Am J Clin Pathol 1999;111:S94-S103. (Pubitemid 29024954)
18. Hyjek E, Smith WJ, Isaacson PG. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis. Hum Pathol 1988;19:766-776.
19. van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007;21:201-206. (Pubitemid 46158110)
20. Langerak AW, Molina TJ, Lavender FL, et al. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2007;21:222-229. (Pubitemid 46158113)
21. Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigendriven lymphoproliferation. Blood 2006;107:3034-3044.
22. Frieder D, Larijani M, Tang E, et al. Antibody diversifi cation: mutational mechanisms and oncogenesis. Immunol Res 2006;35: 75-88. (Pubitemid 44547504)
23. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577. (Pubitemid 23259233)
24. Enno A, O ' Rourke J, Braye S, et al. Antigen-dependent progression of mucosa-associated lymphoid tissue (MALT)-type lymphoma in the stomach. Effects of antimicrobial therapy on gastric MALT lymphoma in mice. Am J Pathol 1998;152:1625-1632. (Pubitemid 28275020)
25. Mueller A, O' R ourke J, Chu P, et al. The role of antigenic drive and tumor-infi ltrating accessory cells in the pathogenesis of helicobacterinduced mucosa-associated lymphoid tissue lymphoma. Am J Pathol 2005;167:797-812. (Pubitemid 41216363)
26. Craig VJ, Arnold I, Gerke C, et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 2010;115:581-591.
27. Nardini E, Aiello A, Giardini R, et al. Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas. Blood 2000;95:1032-1038. (Pubitemid 30062728)
28. Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diff use large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood 2007;109:3500-3504. (Pubitemid 46572541)
29. Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosaassociated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000;95:3878-3884. (Pubitemid 30412863)
30. Perez M, Pacchiarotti A, Frontani M, et al. Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4- 59 segments. Br J Dermatol 2010;162:611-618.
31. Silverman GJ, Goni F, Fernandez J, et al. Distinct patterns of heavy chain variable region subgroup use by human monoclonal autoantibodies of diff erent specifi city. J Exp Med 1988;168:2361-2366. (Pubitemid 19020912)
32. Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin' s lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005;201: 1229-1241. (Pubitemid 40629067)
33. Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing diff erent antibody reactivity. J Clin Invest 2005;115:1636-1643. (Pubitemid 40814672)
34. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700-2707. (Pubitemid 46482061)
35. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosaassociated lymphoid tissue lymphoma. J Clin Oncol 2005;23: 6370-6378. (Pubitemid 46218849)
36. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-1176.
37. Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998;338:804-810. (Pubitemid 28135987)
38. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239-248. (Pubitemid 38067636)
39. Cerroni L, Zochling N, Putz B, et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997; 24:457-461. (Pubitemid 27432373)
40. Chanudet E, Zhou Y, Bacon CM, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in diff erent geographical regions. J Pathol 2006;209:344-351. (Pubitemid 43997743)
41. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586-594. (Pubitemid 38584982)
42. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-1131.
43. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-1271. (Pubitemid 24129959)
44. Wotherspoon AC. Gastric lymphoma, carcinoma and Helicobacter pylori. J R Soc Med 1995;88:302-303.
45. Wotherspoon AC. Gastric MALT lymphoma and Helicobacter pylori. Yale J Biol Med 1996;69:61-68. (Pubitemid 27076710)
46. Spencer J, Wotherspoon AC. Gastric MALT lymphoma and Helicobacter pylori. Cancer Surv 1997;30:213-231. (Pubitemid 27371544)
47. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004;113:321-333. (Pubitemid 38544173)
48. Wotherspoon AC, Doglioni C, de Boni M, et al. Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet 1994;343:1503. (Pubitemid 24176352)
49. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosaassociated lymphoid tissue. Ann Intern Med 1995;122:767-769.
50. Bayerdorff er E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995;345:1591-1594.
51. D'Elios MM, Appelmelk BJ, Amedei A, et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004;10:316-323. (Pubitemid 38881520)
52. D'E lios MM, Bergman MP, Amedei A, et al. Helicobacter pylori and gastric autoimmunity. Microbes Infect 2004;6:1395-1401. (Pubitemid 41110583)
53. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005;105:2274-2280. (Pubitemid 40387019)
54. Al-Bahrani Z, Al-Saleem T, Al-Mondhiry H, et al. Alpha heavy chain disease (report of 18 cases from Iraq). Gut 1978;19:627-631.
55. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000;24:1279-1285.
56. Garbe C, Stein H, Dienemann D, et al. Borrelia burgdorferiassociated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991;24:584-590.
57. Vega JH, Vega F, Rassidakis G, et al. Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol 2006;125(Suppl.): S38-S49.
58. Kutting B, Bonsmann G, Metze D, et al. Borrelia burgdorferiassociated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997;36:311-314. (Pubitemid 27078893)
59. Colli C, Leinweber B, Mullegger R, et al. Borrelia burgdorferiassociated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol 2004;31:232-240. (Pubitemid 38230565)
60. Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000;31:263-268. (Pubitemid 30090662)
61. Goodlad JR, Davidson MM, Hollowood K, et al. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology 2000;37:501-508. (Pubitemid 32099161)
62. Slater DN. Borrelia burgdorferi-associated primary cutaneous B-cell lymphoma. Histopathology 2001;38:73-77. (Pubitemid 32126192)
63. Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001;28:502-507. (Pubitemid 33020611)
64. Li C, Inagaki H, Kuo TT, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 Asian cases. Am J Surg Pathol 2003;27:1061-1069. (Pubitemid 36909527)
65. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol 2005;141:1139-1145. (Pubitemid 41373960)
66. Picken RN, Strle F, Ruzic-Sabljic E, et al. Molecular subtyping of Borrelia burgdorferi sensu lato isolates from fi ve patients with solitary lymphocytoma. J Invest Dermatol 1997;108:92-97. (Pubitemid 27019852)
67. Breier FH, Aberer E, Stanek G, et al. Isolation of Borrelia afzelii from circumscribed scleroderma. Br J Dermatol 1999;140:925-930. (Pubitemid 29238469)
68. Ozkan S, Atabey N, Fetil E, et al. Evidence for Borrelia burgdorferi in morphea and lichen sclerosus. Int J Dermatol 2000;39:278-283. (Pubitemid 30260806)
69. Liang FT, Nelson FK, Fikrig E. Molecular adaptation of Borrelia burgdorferi in the murine host. J Exp Med 2002;196:275-280. (Pubitemid 34787518)
70. Wooten RM, Modur VR, McIntyre TM, et al. Borrelia burgdorferi outer membrane protein A induces nuclear translocation of nuclear factor-kappa B and infl ammatory activation in human endothelial cells. J Immunol 1996;157:4584-4590. (Pubitemid 126449380)
71. Wooten RM, Ma Y, Yoder RA, et al. Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol 2002;168:348-355. (Pubitemid 34014136)
72. Yeung L, Tsao YP, Chen PY, et al. Combination of adult inclusion conjunctivitis and mucosa-associated lymphoid tissue (MALT) lymphoma in a young adult. Cornea 2004;23:71-75. (Pubitemid 38031878)
73. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst 2006;98:1375-1382. (Pubitemid 44530714)
74. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis 2003;167:177-185. (Pubitemid 36773518)
75. Abbondanzo SL. Extranodal marginal-zone B-cell lymphoma of the salivary gland. Ann Diagn Pathol 2001;5:246-254. (Pubitemid 32783333)
76. Chehata S, Laatiri MA, Bouaouina N, et al. [Gougerot-Sjogren syndrome disclosed by MALT lymphoma of the salivary glands. Report of 3 cases]. Ann Med Interne (Paris) 2000;151:93-96. (Pubitemid 30337009)
77. Pedersen RK, Pedersen NT. Primary non-Hodgkin ' s lymphoma of the thyroid gland: a population based study. Histopathology 1996; 28:25-32. (Pubitemid 26040138)
78. Aozasa K. Hashimoto' s thyroiditis as a risk factor of thyroid lymphoma. Acta Pathol Jpn 1990;40:459-468. (Pubitemid 20295348)
79. Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto ' s thyroiditis. Hum Pathol 1988; 19:1315-1326. (Pubitemid 19005633)
80. Anscombe AM, Wright DH. Primary malignant lymphoma of the thyroid-A tumor of mucosa-associated lymphoid tissue: review of seventy-six cases. Histopathology 1985;9:81-97. (Pubitemid 15170642)
81. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren ' s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90:766-775. (Pubitemid 27299117)
82. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985;312:601-604. (Pubitemid 15133674)
83. Kovacs L, Szodoray P, Kiss E. Secondary tumors in Sjogren' s syndrome. Autoimmun Rev 2010;9:203-206.
84. Addis BJ, Hyjek E, Isaacson PG. Primary pulmonary lymphoma: a re-appraisal of its histogenesis and its relationship to pseudolymphoma and lymphoid interstitial pneumonia. Histopathology 1988;13:1-17.
85. Schwartz IS, Strauchen JA. Lymphocytic mastopathy. An autoimmune disease of the breast? Am J Clin Pathol 1990;93:725-730. (Pubitemid 20180930)
86. Lammie GA, Bobrow LG, Staunton MD, et al. Sclerosing lymphocytic lobulitis of the breast-evidence for an autoimmune pathogenesis. Histopathology 1991;19:13-20.
87. Aozasa K, Ohsawa M, Saeki K, et al. Malignant lymphoma of the breast. Immunologic type and association with lymphocytic mastopathy. Am J Clin Pathol 1992;97:699-704.
88. Du MQ. MALT lymphoma: many roads lead to nuclear factorkappab activation. Histopathology 2011;58:26-38.
89. Th ome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol 2004;4:348-359. (Pubitemid 38649277)
90. Moreno-Garcia ME, Sommer KM, Bandaranayake AD, et al. Proximal signals controlling B-cell antigen receptor (BCR) mediated NF-kappaB activation. Adv Exp Med Biol 2006;584:89-106.
91. Rawlings DJ, Sommer K, Moreno-Garcia ME. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 2006;6:799-812. (Pubitemid 44631649)
92. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288. (Pubitemid 38610351)
93. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in infl ammation and immunity. J Biol Chem 2009;284:8217-8221.
94. Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood 1995;85:2000-2004.
95. Murga Penas EM, Hinz K, Roser K, et al. Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas. Leukemia 2003;17:2225-2229. (Pubitemid 37428391)
96. Streubel B, Lamprecht A, Dierlamm J, et al. t(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003;101:2335-2339. (Pubitemid 36302078)
97. Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of diff erent sites. Leukemia 2004;18:1722-1726. (Pubitemid 39386353)
98. Streubel B, Vinatzer U, Lamprecht A, et al. t(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005;19:652-658. (Pubitemid 40521171)
99. Ye H, Gong L, Liu H, et al. MALT lymphoma with t(14;18) (q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol 2005;205:293-301. (Pubitemid 40253919)
100. Sagaert X, Laurent M, Baens M, et al. MALT1 and BCL10 aberrations in MALT lymphomas and their Effect on the expression of BCL10 in the tumor cells. Mod Pathol 2006;19:225-232. (Pubitemid 43117606)
101. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specifi city of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 2000;156:1183-1188. (Pubitemid 30659996)
102. Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18) (q21;q21) in MALT lymphomas of diff erent sites: signifi cant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003;102:1012-1018. (Pubitemid 36917798)
103. Levine EG, Arthur DC, Machnicki J, et al. Four new recurring translocations in non-Hodgkin lymphoma. Blood 1989;74:1796-1800. (Pubitemid 19251562)
104. Streubel B, Ye H, Du MQ, et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004;66:476-480. (Pubitemid 39370239)
105. Schreuder MI, Hoeve MA, Hebeda KM, et al. Mutual exclusion of t(11;18)(q21;q21) and numerical chromosomal aberrations in the development of diff erent types of primary gastric lymphomas. Br J Haematol 2003;123:590-599. (Pubitemid 37468054)
106. Liu H, Ye H, Dogan A, et al. t(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001;98:1182-1187.
107. Baens M, Maes B, Steyls A, et al. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 2000;156:1433-1439. (Pubitemid 30660018)
108. Maes B, Baens M, Marynen P, et al. The product of the t(11;18), an API2-MLT fusion, is an almost exclusive fi nding in marginal zone cell lymphoma of extranodal MALT-type. Ann Oncol 2000;11:521-526. (Pubitemid 30431372)
109. Dierlamm J, Baens M, Stefanova-Ouzounova M, et al. Detection of t(11;18)(q21;q21) by interphase fl uorescence in situ hybridization using API2 and MLT specifi c probes. Blood 2000;96:2215-2218.
110. Motegi M, Yonezumi M, Suzuki H, et al. API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am J Pathol 2000;156: 807-812. (Pubitemid 30626938)
111. Auer IA, Gascoyne RD, Connors JM, et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol 1997;8:979-985. (Pubitemid 27475729)
112. Okabe M, Inagaki H, Ohshima K, et al. API2-MALT1 fusion defi nes a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Am J Pathol 2003;162:1113-1122. (Pubitemid 36350657)
113. Huang X, Zhang Z, Liu H, et al. t(11;18)(q21;q21) in gastric MALT lymphoma and diff use large B-cell lymphoma of Chinese patients. Hematol J 2003;4:342-345. (Pubitemid 37259352)
114. Toracchio S, Ota H, de Jong D, et al. Translocation t(11;18) (q21;q21) in gastric B-cell lymphomas. Cancer Sci 2009;100:881-887.
115. Rosenwald A, Ott G, Stilgenbauer S, et al. Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal zone B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas. Am J Pathol 1999;155:1817-1821.
116. Remstein ED, Kurtin PJ, James CD, et al. Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosaassociated lymphoid tissue lymphomas with aneuploidy develop along diff erent pathogenetic pathways. Am J Pathol 2002;161:63-71. (Pubitemid 34760771)
117. Remstein ED, Kurtin PJ, Einerson RR, et al. Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1. Leukemia 2004;18:156-160. (Pubitemid 38159452)
118. Liu H, Ye H, Ruskone-Fourmestraux A, et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002;122:1286-1294. (Pubitemid 34465171)
119. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40. (Pubitemid 32056501)
120. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin ' s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-1983. (Pubitemid 46211377)
121. Roy N, Deveraux QL, Takahashi R, et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specifi c caspases. EMBO J 1997;16:6914-6925. (Pubitemid 27520792)
122. Hu S, Du MQ, Park SM, et al. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 2006;116:174-181. (Pubitemid 43121802)
123. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999;13:239-252.
124. Garrison JB, Samuel T, Reed JC. TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 2009;28:1584-1593.
125. Noels H, van Loo G, Hagens S, et al. A novel TRAF6 binding site in MALT1 defi nes distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions. J Biol Chem 2007;282:10180-10189. (Pubitemid 47093445)
126. Wotherspoon AC, Soosay GN, Diss TC, et al. Low-grade primary B-cell lymphoma of the lung. An immunohistochemical, molecular, and cytogenetic study of a single case. Am J Clin Pathol 1990;94: 655-660. (Pubitemid 20369734)
127. Du MQ, Peng H, Liu H, et al. BCL10 gene mutation in lymphoma. Blood 2000;95:3885-3890. (Pubitemid 30412864)
128. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-653. (Pubitemid 39025059)
129. Lucas PC, Yonezumi M, Inohara N, et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem 2001;276:19012-19019.
130. Bhattacharyya S, Borthakur A, Dudeja PK, et al. Lipopolysaccharide- induced activation of NF-kappaB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations. Exp Cell Res 2010;316:3317-3327.
131. Kuo SH, Yeh PY, Chen LT, et al. Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pyloriindependent growth of gastric diff use large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood 2008;112:2927-2934.
132. Li Z, Wang H, Xue L, et al. Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma. Blood 2009;114:4158-4168.
133. Achuthan R, Bell SM, Leek JP, et al. Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma. Genes Chromosomes Cancer 2000;29:347-349.
134. Sanchez-Izquierdo D, Buchonnet G, Siebert R, et al. MALT1 is deregulated by both chromosomal translocation and amplifi cation in B-cell non-Hodgkin lymphoma. Blood 2003;101:4539-4546. (Pubitemid 36857825)
135. Tusche MW, Ward LA, Vu F, et al. Diff erential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J Exp Med 2009;206:2671-2683.
136. Nakagawa M, Hosokawa Y, Yonezumi M, et al. MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10. Blood 2005;106:4210-4216. (Pubitemid 41775928)
137. Barrans SL, Fenton JA, Banham A, et al. Strong expression of FOXP1 identifi es a distinct subset of diff use large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933-2935. (Pubitemid 39434982)
138. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diff use large B-cell lymphoma. Clin Cancer Res 2005;11:1065-1072. (Pubitemid 40175755)
139. Fenton JA, Schuuring E, Barrans SL, et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diff use large B-cell lymphoma. Genes Chromosomes Cancer 2006;45:164-168. (Pubitemid 43191023)
140. Ye H, Remstein ED, Bacon CM, et al. Chromosomal translocations involving BCL6 in MALT lymphoma. Haematologica 2008;93:145-146. (Pubitemid 351156167)
141. Chen YW, Hu XT, Liang AC, et al. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Blood 2006;108:2373-2383. (Pubitemid 44497522)
142. Chanudet E, Ye H, Ferry J, et al. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol 2009;217:420-430.
143. Chanudet E, Huang Y, Ichimura K, et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010;24:483-487.
144. Novak U, Rinaldi A, Kwee I, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009;113: 4918-4921.
145. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-716.
146. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diff use large B-cell lymphoma. Nature 2009;459:717-721.
147. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009;114:2467-2475.
148. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981-989.
149. Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008;40:1059-1061.
150. Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008;40:1062-1064.
151. Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, et al. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res Ther 2009;11:R42.
152. Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007;39:1477-1482. (Pubitemid 350191346)
153. Musone SL, Taylor KE, Nititham J, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011;12:176-182.
154. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009;30:383-391.
155. Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010;9:195-199.
156. Brynes RK, Almaguer PD, Leathery KE, et al. Numerical cytogenetic abnormalities of chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol 1996;9:995-1000. (Pubitemid 26356742)
157. Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of diff erent sites share similar cytogenetic and morphologic features. Blood 1996;87:299-307. (Pubitemid 26011844)
158. Vinatzer U, Gollinger M, Mullauer L, et al. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res 2008;14:6426-6431.
159. Novak A, Akasaka T, Manske M, et al. Elevated expression of GPR34 and its association with a novel translocation t(X;14)(p11;q32) involving IgHS and GPR34 in MALT lymphoma. Blood 2008:112(Suppl. 1): Abstract 2251.
160. Baens M, Fevery S, Sagaert X, et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res 2006;66:5270-5277. (Pubitemid 43844951)
161. Hamoudi RA, Appert A, Ye H, et al. Diff erential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 2010;24:1487-1497.
162. Ye H, Gong L, Liu H, et al. Strong BCL10 nuclear expression identifi es gastric MALT lymphomas that do not respond to H pylori eradication. Gut 2006;55:137-138.
163. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-2495. (Pubitemid 36857603)
164. Th ieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997;15:1624-1630. (Pubitemid 27167402)
165. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin ' s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin ' s Lymphoma Classifi cation Project. J Clin Oncol 1998;16:2780-2795. (Pubitemid 28363044)
166. Th ieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802-806. (Pubitemid 30062699)
167. Sheibani K, Burke JS, Swartz WG, et al. Monocytoid B-cell lymphoma. Clinicopathologic study of 21 cases of a unique type of lowgrade lymphoma. Cancer 1988;62:1531-1538.
168. Du M, Peng H, Singh N, et al. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995;86:4587-4593.
169. Martinez-Delgado B, Robledo M, Arranz E, et al. Hypermethylation of p15/ink4b/MTS2 gene is diff erentially implicated among non-Hodgkin' s lymphomas. Leukemia 1998;12:937-941. (Pubitemid 28287218)
170. Martinez-Delgado B, Fernandez-Piqueras J, Garcia MJ, et al. Hypermethylation of a 5 ' CpG island of p16 is a frequent event in non- Hodgkin' s lymphoma. Leukemia 1997;11:425-428. (Pubitemid 27120994)
171. Neumeister P, Hoefl er G, Beham-Schmid C, et al. Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. Gastroenterology 1997;112:1871-1875. (Pubitemid 27240773)
172. Stolte M, Bayerdorff er E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut 2002;50(Suppl. 3):III19-III24. (Pubitemid 34407452)
173. Zucca E, Dreyling M. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4):113-114.
174. Zucca E, Bertoni F, Roggero E, et al. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000;96:410-419. (Pubitemid 30463357)
175. Hancock BW, Qian W, Linch D, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 2009;144:367-375.
176. Zenahlik P, Fink-Puches R, Kapp KS, et al. [Therapy of primary cutaneous B-cell lymphomas]. Hautarzt 2000;51:19-24. (Pubitemid 30163111)
177. Bogle MA, Riddle CC, Triana EM, et al. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol 2005;53:479-484. (Pubitemid 41195972)
178. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005;23:5067-5073. (Pubitemid 46224014)
179. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008;112:1600-1609.
180. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001;50:1258-1264. (Pubitemid 32727804)
181. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosaassociated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16:1916-1921. (Pubitemid 28234741)
182. Cozzio A, Kempf W, Schmid-Meyer R, et al. Intra-lesional lowdose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma 2006;47:865-869. (Pubitemid 43840642)
183. Fink-Puches R, Wolf IH, Zalaudek I, et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005;52:847-853. (Pubitemid 40614650)
184. Kerl K, Prins C, Saurat JH, et al. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti- CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 2006;155:1197-1200. (Pubitemid 44729995)
185. Kyrtsonis MC, Siakantaris MP, Kalpadakis C, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol 2006;77:300-303. (Pubitemid 44337322)
186. Hammel P, Haioun C, Chaumette MT, et al. Effi cacy of singleagent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-2529.
187. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20:3872-3877.
188. Conconi A, Martinelli G, Th ieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745. (Pubitemid 37248842)
189. Zucca E, Conconi E, Martelli M, et al. Interim analysis of the IELSG-19 randomised study of chlorambucil plus rituximab versus rituximab alone in extranodal marginal zone lymphomas of mucosaassociated tissue (MALT lymphoma). Blood 2009;114(Suppl. 1): Abstract 21716.
190. Zinzani PL. Clinical experience with fl udarabine in indolent non-Hodgkin ' s lymphoma. Hematol J 2004;5(Suppl. 1):S38-S49. (Pubitemid 38744819)
191. Klasa RJ, Meyer RM, Shustik C, et al. Randomized phase III study of fl udarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin ' s lymphoma previously treated with an alkylating agent or alkylatorcontaining regimen. J Clin Oncol 2002;20:4649-4654. (Pubitemid 36025281)
192. Hagenbeek A, Eghbali H, Monfardini S, et al. Phase III intergroup study of fl udarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin ' s lymphoma. J Clin Oncol 2006;24:1590-1596. (Pubitemid 46646221)
193. Zinzani PL, Magagnoli M, Moretti L, et al. Randomized trial of fl udarabine versus fl udarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000;18:773-779. (Pubitemid 30106607)
194. Lazzarino M, Orlandi E, Montillo M, et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin ' s lymphoma. Ann Oncol 1999;10:59-64. (Pubitemid 29090593)
195. Santini G, Nati S, Spriano M, et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin ' s lymphoma. Haematologica 2001;86:282-286. (Pubitemid 32291066)
196. Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 2002;100:4351-4357. (Pubitemid 35429673)
197. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997;53:1005-1037. (Pubitemid 27254575)
198. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996;14:1262-1268. (Pubitemid 26105534)
199. Anderson VR, Perry CM. Fludarabine: a review of its use in non- Hodgkin' s lymphoma. Drugs 2007;67:1633-1655. (Pubitemid 47271880)
200. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-360. (Pubitemid 38579481)
201. Panwalkar A, Verstovsek S, Giles F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004;100:1578-1589. (Pubitemid 38456332)
202. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-639. (Pubitemid 46224241)
203. Troch M, Jonak C, Mullauer L, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009; 94:738-742.
204. Conconi A, Martinelli G, Lopez-Guillermo A, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 2011;22:689-695.
205. Tilly H, Dreyling M. Diff use large B-cell non-Hodgkin ' s lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4):110-112.
206. Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999;17:1254.